Detalhe da pesquisa
1.
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Haematologica
; 108(2): 532-542, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35979720
2.
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.
Eur J Haematol
; 110(6): 633-638, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788756
3.
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Br J Haematol
; 194(2): 319-324, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34060069
4.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Blood
; 132(20): 2115-2124, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181172
5.
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
Am J Hematol
; 95(12): 1553-1561, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894785
6.
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Br J Haematol
; 181(6): 782-790, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29741758
7.
Targeted treatment of immune thrombocytopenia in CTLA-4 insufficiency: a case report.
Br J Haematol
; 196(3): e42-e45, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34628649
8.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Br J Haematol
; 179(1): 83-97, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677895
9.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Ann Hematol
; 96(12): 2025-2029, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28975386
10.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol
; 92(10): 1037-1046, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28675513
11.
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Br J Haematol
; 174(1): 88-101, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991631
12.
Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
Ann Hematol
; 95(1): 73-78, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26453076
13.
Practical Management of Castleman's Disease.
Acta Haematol
; 136(1): 16-22, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27160307
14.
Thermodynamics of hybrid quantum rotor devices.
Phys Rev E
; 109(2-1): 024108, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38491686
15.
Castleman disease: delineating the spectrum.
Br J Haematol
; 180(2): 173-174, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29143317
16.
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Leuk Lymphoma
; 64(3): 651-661, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606533
17.
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Leuk Res
; 134: 107390, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776843
18.
Active transport nanochelators for the reduction of liver iron burden in iron overload.
J Control Release
; 350: 857-869, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36058353
19.
Management of patients with lower-risk myelodysplastic syndromes.
Blood Cancer J
; 12(12): 166, 2022 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36517487
20.
Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy.
Curr Oncol
; 29(10): 6794-6806, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36290812